Project Grant HT94252310325
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$636K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
The University of California, Davis was awarded a $1,446,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on "THERAPEUTIC TARGETING OF A NOVEL TUMOR-INTRINSIC SIGNALING PATHWAY FOR LETHAL PROSTATE CANCER." The award period is from August 1, 2023 to July 31, 2026. UC Davis will leverage its expertise in medical research to investigate potential medical solutions relevant to the...
The University of California, Davis was awarded a $1,446,009 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to target CD200/CD200R signaling as a novel strategy for treating therapy-resistant prostate cancer. The grant, awarded July 1, 2023 and set to be completed by June 30, 2026, will support research into medical solutions for prostate cancer that remains unresponsive to standard treatments by...
The University of California, Davis was awarded a $1,177,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research to target a key tumor plasticity driver in lethal prostate cancer. Through August 2021 to July 2024, UC Davis researchers will investigate medical solutions for prostate cancer on the cellular level with the aim of transforming patient care and outcomes. The...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This federal Project Grant award, totaling $1,163,420.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Davis. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research aims to investigate functional and phenotypic metabolic transitions governing disease state in clear cell renal cell...
The Regents of the University of California, San Francisco was awarded a $484,500 Project Grant from the Defense Health Agency to support research titled "Synergistic Combination Treatment of Prostate Cancer Using CD46- Targeted Antibody-Drug Conjugate and Radioimmunotherapy." The two-year award beginning March 1, 2023 will fund the development of innovative medical solutions for prostate cancer through the Military Medical Research and Development program (CFDA 12.420). This program...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,453,501.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) on June 1, 2024. The grant supports the development of "Targeted Theranostic Nanopolymers for Imaging and Alpha Radiopharmaceutical Therapy of Prostate Cancer" over a period of 3 years through May 31, 2027. As a leading academic medical center, UCSF will leverage its expertise in biomedical...
The federal Project Grant award, titled "CONTRIBUTION OF BONE MASS AND FRACTURE TO BONE METASTASIS IN PROSTATE CANCER," was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $1,801,179.00 award, granted on Apr 15, 2025, supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The project, conducted by the...